Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor - Related Studies

Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor

This study is ongoing, but not recruiting participants.

Study NCT00021047. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Esophageal Cancer
		Extrahepatic Bile Duct Cancer
		Gastric Cancer
		Head and Neck Cancer
		Liver Cancer

2	Additional conditions recognized in this trial
		Bile Duct Neoplasms
		Esophageal Diseases
		Esophageal Neoplasms
		Head and Neck Neoplasms
		Liver Neoplasms
		Stomach Neoplasms

3	More general conditions related to this trial
		Bile Duct Diseases
		Biliary Tract Diseases
		Biliary Tract Neoplasms
		Digestive System Diseases
		Digestive System Neoplasms
		Gastrointestinal Diseases
		Gastrointestinal Neoplasms
		Liver Diseases
		Neoplasms
		Neoplasms by Site
		Stomach Diseases

4	Interventions listed in this trial
		capecitabine
		carboplatin
		epirubicin hydrochloride

5	Additional drug interventions recognized in this trial
		Epirubicin

6	More general drug interventions related to this trial
		Antibiotics, Antineoplastic
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

7	Sponsors listed in this trial
		National Cancer Institute (NCI)